13 June 2018 - In oncology clinical trials, cross-over is used frequently but may lead to uncertainties regarding treatment effects. ...
13 June 2018 - IQWiG employees criticise the publication practice of PALOMA-2 study authors. ...
4 January 2018 - Four dossier assessments involving comparisons between immunotherapies and chemotherapies for the same therapeutic indication in 2017/comparison ...
16 January 2018 - Germany’s drug assessment body has criticized a lack of data directly comparing drugs in a promising ...
1 September 2017 - Significant benefit for patients with progression during or shortly after platinum-based therapy. ...
15 May 2017 - Patients in the relevant subpopulation of the analysed study survived longer. ...
28 March 2017 - Eisai announced today that the German Federal Joint Committee (G-BA) has confirmed the additional benefit of in-house ...
1 March 2017 - More frequent severe side effects in first-line therapy after menopause/missing data for other patients. ...
4 January 2017 - Approximately 15,000 people in Germany develop renal cell carcinoma every year. ...
2 January 2017 - The dossier does not contain any suitable data for patients with ROS1 positive non-small-cell lung cancer. ...
4 October 2016 - Increased proportion of treatment-change limits further interpretability so the results of the initial IQWiG evaluation shall continue. ...
4 October 2016 - The dossier contains no suitable data on first-line use. ...
15 September 2016 - Survival advantage in BRAF V600 wild type tumour depends on gender / severe side effects more common. ...
15 September 2016 - Drug manufacturer dossier contained no data suitable for the assessment. ...
4 September 2016 - Assessment ignores unprecedented overall survival benefit for eribulin in advanced liposarcoma. ...